Biocryst Pharma Inc BCRX

$7.30 -0.20 (-2.67%)

Valuation

Market cap
1,929,743,000
Revenue TTM
$874,840,000
Net income TTM
$263,860,000
P/E (trailing)
4.87
P/E (forward)
—
Profit margin
30.16%
Debt to equity
-2.09

Trading

Volume
2,954,500
Avg volume
5,434,802
Day's range
$7.28 – $7.64
Shares out
257,299,000
Stochastic %K
4%
Beta
0.55
Analysts
Moderate Buy
Price target
$20.18

Price

Company profile

BioCryst Pharmaceuticals, Inc., a biotechnology company, developing and commercializing medicines for hereditary angioedema (HAE) and other rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated and seasonal influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat HAE. It is als...

Show more

BioCryst Pharmaceuticals, Inc., a biotechnology company, developing and commercializing medicines for hereditary angioedema (HAE) and other rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated and seasonal influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat HAE. It is also developing BCX17725, a protein therapeutic for netherton syndrome which is in phase 1; Avoralstat, an ocular plasma kallikrein inhibitor for diabetic macular edema that is in Phase 1; Navenibart, a monoclonal antibody plasma kallikrein inhibitor for HAE which is in Phase 3; BCX17725, an investigational protein therapeutic KLK5 inhibitor for the treatment of netherton syndrome that is in phase 1 clinical trial; STAR-0310, a monoclonal antibody OX40 antagonist for the treatment of atopic dermatitis which is in Phase 1a trial. The company has collaborations and in-license relationships with the Torii Pharmaceutical Co., Ltd., Shionogi & Co., Ltd., and Green Cross Corporation; National Institute of Allergy and Infectious Diseases; Biomedical Advanced Research and Development Authority; the U.S. Department of Health and Human Services; and Albert Einstein College of Medicine of Yeshiva University and Industrial Research, Ltd. BioCryst Pharmaceuticals, Inc. was founded in 1986 and is headquartered in Durham, North Carolina.

Industry
Drug Manufacturers - Specialty & Generic
Sector
Healthcare
Phone
919 859 1302
Website
https://www.biocryst.com
Address
4505 Emperor Boulevard, Suite 200, Durham, United States

Latest news

Stocktwits

Paulzk Nov 19, 4:52 AM
$BCRX Bullshit stock price Market Cap (intraday) 1.878B Revenue (ttm) 961.51M price to sales 1.953
0 replies
Paulzk Nov 19, 1:54 AM
$BCRX Pfizer is undertaking yet another deal in China to get into a budding area of research, using "in vivo" cell therapy for autoimmune diseases. Under the terms of the agreement with Starna Therapeutics, Pfizer will obtain exclusive rights outside Greater China to three preclinical programs focused on autoimmune diseases. It will also get the rights to use Starna's technology in inflammation, immunology and oncology as well as options to license other projects and expand its territory to include Greater China. Pfizer will pay Starna $330 million up front and offer as much as $2.3 billion more in payments for reaching certain development and commercial milestones. https://finance.yahoo.com/healthcare/articles/pfizer-leaps-vivo-car-t-155500147.html
0 replies
Del_Gue Nov 19, 1:50 AM 0 replies
Fergus20 Nov 19, 12:55 AM
$BCRX burn and die
0 replies
Fergus20 Nov 18, 11:45 PM
$BCRX nobody does a goddamn thing here. I’ve sent over 950 emails to investor relations.
1 replies
Fergus20 Nov 18, 11:44 PM
$BCRX looks really strong after hours
0 replies
MaxNoob Nov 18, 11:01 PM
$BCRX A profitable company that will do over 700M in revenue and it can barely trade at a 1.8B MC. Management here should be embarrassed and ashamed, but I doubt they are either of those things. probably because they get to keep cashing their fat paychecks.
1 replies
2YrsEarly Nov 18, 9:41 PM
$BCRX Very discouraging (and incompetent IMO) of management not to do a stock buyback plan or insiders purchase shares on the open market if they truly felt the equity price was a screaming buy. Their lack of action regarding the equity performance is destroying investor confidence and creating uncertainty.
1 replies